Samsung Bioepis has published positive Phase I and Phase III trial results for its SB16 proposed biosimilar to Prolia (denosumab) at the annual meeting of the American Society for Bone and Mineral Research.
The randomized, double-blind, three-arm, multi-center, parallel group and single-dose Phase I study for SB16 “demonstrates pharmacokinetic bioequivalence between SB16, EU-sourced denosumab, and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?